Lorlatinib

About Lorlatinib (CAS 1454846-35-5)

Lorlatinib (CAS 1454846-35-5) is a third-generation ALK and ROS1 tyrosine kinase inhibitor developed to target oncogenic signaling pathways associated with certain types of lung cancer. Known in research as pf-06463922 and sometimes referenced as pf 06463922, the compound is widely studied for its ability to inhibit kinase mutations that drive tumor growth and therapeutic resistance. As a lorlatinib small molecule, it demonstrates strong selectivity and potency against multiple ALK variants.

Researchers frequently analyze the lorlatinib chemical structure to understand how the compound interacts with kinase domains and overcomes resistance mutations. The lorlatinib molecular formula and lorlatinib molecular weight are well documented, enabling precise experimental design in biochemical and pharmacological studies. Laboratories involved in oncology research often buy 1454846-35-5 as a reference compound for kinase inhibitor screening and signaling pathway investigations.

Application Lorlatinib

Lorlatinib is widely used in biomedical research focused on kinase-driven cancers, particularly those associated with ALK and ROS1 gene alterations. Its strong activity against resistant mutations makes it an important tool in targeted therapy research.

• Research on ALK and ROS1 kinase signaling pathways
• Investigation of resistance mechanisms in targeted cancer therapies
• Screening and validation of tyrosine kinase inhibitors
• Studies of oncogenic signaling and tumor progression

In Vitro

In vitro experiments demonstrate that pf-06463922 small molecule effectively inhibits ALK and ROS1 kinase activity in cultured cancer cell lines. By blocking downstream signaling pathways such as PI3K/AKT and MAPK, Lorlatinib suppresses proliferation and survival signals that support tumor development. These properties make the compound valuable for evaluating targeted inhibition strategies.

In Vivo

In vivo studies have shown that inhibition of oncogenic kinase signaling by Lorlatinib can reduce tumor growth in preclinical models. The compound demonstrates activity against multiple resistance mutations, allowing researchers to investigate advanced strategies for overcoming therapeutic resistance in cancer treatment.

Biochem/physiol Actions

The biochemical mechanism of Lorlatinib is based on selective inhibition of ALK and ROS1 tyrosine kinases. By preventing phosphorylation of downstream signaling proteins, the compound interrupts cellular pathways responsible for uncontrolled proliferation and survival of malignant cells. Research frequently references pf-6463922 pf-06463922 loratinib in studies examining advanced kinase inhibition strategies.

Features and Benefits Lorlatinib

• Potent inhibitor of ALK and ROS1 tyrosine kinases
• Effective tool for studying kinase mutation resistance
• Suitable for both in vitro and in vivo research models
• Widely used reference compound in oncology research

High-quality bioactive molecules are essential for modern pharmaceutical and academic research. Access to reliable compounds allows scientists to investigate signaling pathways, validate therapeutic targets, and accelerate discovery programs aimed at developing next-generation targeted treatments.